168 related articles for article (PubMed ID: 24584025)
1. [Relationship between the effectiveness and dose of micafungin in the treatment of candidemia].
Sugawara T; Murakami N; Uetake N; Matsumoto S; Miyamori S; Okamoto R; Hiraki K
Yakugaku Zasshi; 2014; 134(3):433-8. PubMed ID: 24584025
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL
Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia.
Ota Y; Tatsuno K; Okugawa S; Yanagimoto S; Kitazawa T; Fukushima A; Tsukada K; Koike K
J Infect Chemother; 2007 Aug; 13(4):208-12. PubMed ID: 17721682
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
8. Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species.
Zaki A; Gonzales-Luna AJ; Beyda ND; Lasco T; Garey KW
Pharmacotherapy; 2023 Jun; 43(6):466-472. PubMed ID: 37067155
[TBL] [Abstract][Full Text] [Related]
9. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
11. [In vitro antifungal activity of micafungin].
Quindós G; Eraso E; Javier Carrillo-Muñoz A; Cantón E; Pemán J
Rev Iberoam Micol; 2009 Mar; 26(1):35-41. PubMed ID: 19463275
[TBL] [Abstract][Full Text] [Related]
12. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM
Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680
[TBL] [Abstract][Full Text] [Related]
13. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
14. Development of New Strategies for Echinocandins: Progress in Translational Research.
Walsh TJ; Azie N; Andes DR
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
[TBL] [Abstract][Full Text] [Related]
15. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.
Saraya T; Tanabe K; Araki K; Yonetani S; Makino H; Watanabe T; Tsujimoto N; Takata S; Kurai D; Ishii H; Miyazaki Y; Takizawa H; Goto H
J Clin Microbiol; 2014 Jul; 52(7):2709-12. PubMed ID: 24789192
[TBL] [Abstract][Full Text] [Related]
17. [Could antifungal lock be useful in the management of candidiasis linked with catheters?].
Cateau E; Rodier MH; Imbert C
Med Sci (Paris); 2012; 28(8-9):740-5. PubMed ID: 22920876
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
